



3-4-05

RCE/ELW 1635

PTO/SB/30 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

# Request for Continued Examination (RCE) Transmittal

Address to:  
Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

|                        |                |
|------------------------|----------------|
| Application Number     | 09/214,371     |
| Filing Date            | March 26, 1999 |
| First Named Inventor   | David LANE     |
| Art Unit               | 1635           |
| Examiner Name          | Jane J. ZARA   |
| Attorney Docket Number | 39749.0002     |

**This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.**  
Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. **Submission required under 37 CFR 1.114** Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).
- a. ☐ Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.
- i. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on \_\_\_\_\_
- ii. ☐ Other \_\_\_\_\_
- b. ☒ Enclosed
- i. ☒ Amendment/Reply
- iii. ☒ Information Disclosure Statement (IDS)
- ii. ☐ Affidavit(s)/ Declaration(s)
- iv. ☒ Other ☐ Courtesy Copy of priority specification, as exhibit to amendment/reply; return postcard.
2. **Miscellaneous**
- a. ☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of \_\_\_\_\_ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)
- b. ☐ Other \_\_\_\_\_
3. **Fees** The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.
- The Director is hereby authorized to charge the following fees, or credit any overpayments, to
- a. ☒ Deposit Account No. 08-1641. I have enclosed a duplicate copy of this sheet.
- i. ☒ RCE fee required under 37 CFR 1.17(e)
- ii. ☒ Extension of time fee (37 CFR 1.136 and 1.17) : one (1) month
- iii. ☐ Other \_\_\_\_\_
- b. ☐ Check in the amount of \$ \_\_\_\_\_ enclosed
- c. ☐ Payment by credit card (Form PTO-2038 enclosed)

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

| SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED |                  |                  |               |
|---|------------------|------------------|---------------|
| Signature   |                  | Date             | March 2, 2005 |
| Name (Print/Type)                                   | Daniel M. Becker | Registration No. | 38,376        |

| CERTIFICATE OF EXPRESS MAIL   |  |                                    |               |
|---|--|------------------------------------|---------------|
| I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as Express mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. |  |                                    |               |
| Signature   |  | EXPRESS MAIL NO. EL 993 633 767 US |               |
| Name (Print/Type)   |  | Date                               | March 2, 2005 |

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

03/08/2005 SSITHB1 00000084 081641 09214371

01 FC:1801 790.00 DA



Practitioner's Docket No. : 39749.0002 APC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applic. No.: 09/214,371  
Confirm. No.: 8832 Group Art Unit.: 1635  
Applicant: David LANE *et al.* Examiner: Jane J. ZARA  
Filed: March 26, 1999  
For: INHIBITORS OF THE INTERACTION BETWEEN P53 AND  
MDM2

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Express Mail No.: EL 993 633 767 US  
Mailing Date: March 2, 2005

**AMENDMENT AND RESPONSE ACCOMPANYING RCE**

Sir:

In response to the final Office Action mailed November 3, 2004 in connection with the above-identified patent application, setting a three (3) month shortened statutory period for response, applicants petition currently herewith for a one (1) month extension of time, 37 C.F.R. § 1.136(a), extending time to respond to and including **March 3, 2005**, and file a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114.

Applicants file concurrently herewith a supplemental information disclosure statement (IDS), with copies of the cited references as required, and respectfully submit the following amendments and remarks.

**Amendments to the claims** are reflected in the listing of claims which begins on **page 2** of this paper.

**Remarks** begin on **page 7** of this paper.